We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.75 | -3.57% | 20.25 | 20.00 | 20.50 | 21.50 | 20.25 | 21.00 | 403,566 | 11:52:41 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 7.31 | 18.92M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/7/2017 08:14 | I notice STBX has moved today...up! Probably the knock on effect . | joyjoy13 | |
26/7/2017 08:06 | Three product related r.n.s's in fifteen days and the next one could be the one with larger revenues attached. Multiple products times multiple partners could result in a revenue bearing r.n.s every week...the extra volume and new revenue feeds will take out the seller from lower levels. I just have to sit back and wait... | bobdown2 | |
26/7/2017 07:53 | Ohhhhh, come on! I've only got one tick down... I need two to be special...chuckle! Go get a life....! P.s. Got the biggest walnut tree in back garden...honestly! ( so that will have to do...) | joyjoy13 | |
26/7/2017 07:48 | Don't you just love these sellers :( I hope and believe that one day they will rue their decision to sell All these little deals are just that little deals. But out of small Acorns!! | judijudi | |
26/7/2017 07:28 | Also add in the value of the outstanding IP and potential of sweet healthy sugars (which imho is mind blowing) then you can see why we are where we are currently! In fact I believe undervalued! | f3rdinand | |
26/7/2017 07:25 | But the stock market values shares on future earnings and I think we can all see that (if all goes to plan) then OPTI will easily justify a £50 million mc! Having said that I understand your view and I expect many agree and will be waiting for a multi million deal before jumping on the train! | f3rdinand | |
26/7/2017 07:21 | Since what's his face has altered his fellow traders again... Well... We will just have to wait and see if were traded again today but patience is a virtue IMHO we will rocket one day and we can't be traded as the only way is up. that's my thoughts on the matter but any newbie, please DYOR | joyjoy13 | |
26/7/2017 07:18 | I liked this sentence best . We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL® as the active component in a wide range of pharmaceutical and consumer products around the WORLD. I quote "WORLD" Looking Ab Fab folks.... Well....we knew that anyway! Any doubters now... Well... Be it on their own heads I'm in OPTI and I'm chuffed to bits LTH Good luck all | joyjoy13 | |
26/7/2017 07:17 | F3rdinand- If the current market cap was £5m rather than £50m I wouldn't bother since you're quite right commercialization is just starting but has yet to be proven. I have no problem with the company just the current valuation. Start-ups require fund raisings. Opti will need far more cash. | michaelmouse | |
26/7/2017 07:13 | Your obsession with figures for a company that is literally just starting the commercialisation phase of their business is bizarre imho! | f3rdinand | |
26/7/2017 07:12 | Perhaps they've made so much money they're still counting it out? ;) | michaelmouse | |
26/7/2017 06:59 | Reduced to releasing old news now then. The smell of a fund raise is getting stronger by the day. So that's just two deals announced fairly recently (including this mornings which has previously been released) that probably amounts to less than £500,000 for next year (if you're lucky). That's right 2018, and the market. cap is around £50m. See post 1650. Aimho of course. | michaelmouse | |
26/7/2017 06:52 | Last post from me!Share Prophets on Twitter:Just posted: Optibiotix (#OPTI) starts German sales LPLDL - just look at sales forecasts! Game on! shareprophets.com/30 | parob | |
26/7/2017 06:47 | IFA GMBHWe collect information about medicinal products and pharmacy typical products. These data are continuously kept up-to-date, the market participants technically supported in the performance of legal obligations and contribute to the optimization of logistics within the pharmaceutical distribution chain.We ensure the collection, processing and storage of data duly provided by the supplier, as well as the timely delivery of information services to eligible data users.PZN Pre-allocationWe assign PZN to medicinal products and other pharmacy typical products.The Bundesamt für Verbraucherschutz und Lebensmittelsicherhe | parob | |
26/7/2017 06:30 | OK this isn't 'new' news to this bb (some here have already ordered the capsules!), but it's a way of alerting the wider market that we now have products containing our LP-LDL ingredient on the market (3 months after the initial agreement with HLH was announced) - and this will make other companies take note. We're looking at sales revenues of £200-500K in the near term and growing them. Lets remember sales will also generate revenue from our 50% manufacturing profit share with Sacco. I was hoping they'd RNS this launch. | parob | |
26/7/2017 06:28 | This is just the start of revenues to Opti from such sales. How many other products will come to market that will bring revenue in? Hopefully, the market will start to realise how big Opti could be within a few years from now. | rafboy | |
26/7/2017 06:24 | If we can hit mid six figure numbers for this launch then it won't take many more deals to start getting some serious revenue! In talks with 30 plus companies remember- some of which could be £5 million plus individually! | f3rdinand | |
26/7/2017 06:21 | I also like the fact OPTI are listening to concerns RNSs are mostly predictably announced on Tuesdays.... Thus playing into traders strategy. | elrico | |
26/7/2017 06:18 | The fact SOH is not attempting to use historical sales data for Lactobact® for the new higher cholesterol reduction version, demonstrates the integrity of the man. Many CEO's would have attempted to talk up sales expectation by using Lactobact® historical sales data.HLH clearly have a well established market and now with a jump from 12% claimed cholesterol reduction to a new improved rate of 36% reduction, HLH must be confident for the future sales performance. | elrico | |
26/7/2017 06:16 | Promote them directly to the pharmacy market.......like that part! | bernieboy | |
26/7/2017 06:06 | At last talk of revenues, not high but a start. | deeppockets | |
26/7/2017 06:04 | OptiBiotix Health plc ("OptiBiotix" or the "Company") Market launch for LPLDL® capsules in Germany OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that HLH BioPharma Vertriebs GmbH ("HLH") have achieved product registration of LPLDL® capsules at IFA GmbH and "Bundesamt für Lebensmittelsicherhe This announcement follows on from the three year supply agreement with HLH BioPharma Vertriebs GmbH ("HLH") announced on 15 June 2017. HLH will market capsules containing LPLDL® under the brand name Lactobact® LDL-Control and promote them directly to the pharmacy market in Germany, as well as to consumers on their online platform. Sales revenues are difficult to estimate in this new and developing market but are likely to be in the low to mid six figure in the near term growing as HLH builds market presence. Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to see the first sales of our LPLDL® strain in products available to consumers in Germany. We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL® as the active component in a wide range of pharmaceutical and consumer products around the world. HLH have an international reputation for providing high quality and scientifically validated products and are one of Europe's leading suppliers of probiotics to the pharmacy market. Establishing early sales of LPLDL® to pharmacies with HLH helps substantiate the credibility in the science behind LPLDL® to build the brand and acceptance in the larger consumer healthcare markets." | someuwin | |
26/7/2017 05:51 | Thanks for the post shrewdie. Always good to hear from you and to know that you are still long and strong! | bernieboy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions